# Comparative Effectiveness of Palbociclib Plus AI Versus Fulvestrant for HR+/HER2- ABC

> **NCT05000736** · — · UNKNOWN · sponsor: **Chinese Academy of Medical Sciences** · enrollment: 600 (estimated)

## Conditions studied

- Hormone Receptor Positive Advanced Breast Cancer

## Interventions

- **DRUG:** palbociclib + aromatase inhibitor
- **DRUG:** fulvestrant

## Key facts

- **NCT ID:** NCT05000736
- **Lead sponsor:** Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-09-01
- **Primary completion:** 2022-09-01
- **Final completion:** 2022-09-01
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2022-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05000736

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05000736, "Comparative Effectiveness of Palbociclib Plus AI Versus Fulvestrant for HR+/HER2- ABC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05000736. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*